Highlights Surmodics, Inc.

Equities

SRDX

US8688731004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
41.86 ^USD	-0.21%		-0.45%	+15.16%

03:45pm	Surmodics Signs Group Purchasing Deal With Premier	MT
May. 30	Barrington Research Downgrades SurModics to Market Perform From Outperform	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Lean Lower Premarket Wednesday	May. 29	MT
Sector Update: Health Care	May. 29	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday After Fed Speaker's Hawkish Comments	May. 29	MT
Top Premarket Gainers	May. 29	MT
SurModics Agrees to be Acquired by Private Equity Firm GTCR for $627 Million; Shares Rise Pre-Bell	May. 29	MT
GTCR LLC entered into a definitive agreement to acquire Surmodics, Inc. for approximately $620 million.	May. 28	CI
Top Midday Gainers	May. 01	MT
Earnings Flash (SRDX) SURMODICS Reports Q2 Revenue $32M, vs. Street Est of $28.8M	May. 01	MT
Earnings Flash (SRDX) SURMODICS Reports Q2 EPS $0.07, vs. Street Est of $-0.32	May. 01	MT
Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2024	May. 01	CI
Surmodics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 01	CI
North American Morning Briefing : Traders Wait for -2-	May. 01	DJ
Surmodics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 01	CI
(SRDX) SURMODICS Forecasts Fiscal Year 2024 Revenue Range $117M - $121M	Feb. 01	MT
Earnings Flash (SRDX) SURMODICS Reports Q1 Revenue $30.6M, vs. Street Est of $29.6M	Feb. 01	MT
Earnings Flash (SRDX) SURMODICS Reports Q1 EPS $0.00, vs. Street Est of $-0.30	Feb. 01	MT
Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024	Feb. 01	CI
Surmodics, Inc. Announces Successful Early Clinical Use of its Pounce LP Thrombectomy System	Jan. 22	CI
Surmodics, Inc. Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium	Nov. 16	CI
Surmodics, Inc. Announces 24-Month Data from the Swing Trial Presented At VEITHsymposium	Nov. 16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Surmodics, Inc.

Equities

SRDX

US8688731004

Highlights

Filters